Interestingly, some products have been shown to regulate RIPK1/RIPK3/MLKL-related signaling target protein molecules to inhibit necroptosis and thus inhibit the progression and metastasis of CRC cells (Figure 4). Here, MLKL is linked to colorectal carcinoma.